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Introduction
The development of effective therapies for most subtypes of acute myeloid leukemia (AML) has remained sluggish for decades. Among the many reasons, an essential one is the substantial heterogeneity of this malignancy (1) . Prognosis of AML can be divided into three risk stratifications Several studies and reviews have reported poor prognosis of patients with DNMT3A (6) and TET2 (7) mutation. However, prognostic assessment of IDH mutations was still controversial and needs to be further evaluated. Notably, a meta-analysis performed by Feng et al. (8) containing 15 studies indicated that mutant IDH1 was significantly related to shorter overall survival (OS), whereas in a study from Zhou et al. (9) including 13 studies, the IDH2 mutation was observed to improve OS.
Besides, IDH mutations are particularly common in cytogenetically normal AML patients (CN-AML) (9) . For these reasons, prognostic availability of IDH mutations in IR-AML patients should be further explored. Additionally, several studies, including the one by Wagner et al. (10) , reported the association of the IDH1 single nucleotide polymorphism (SNP) rs11554137 with noticeably poor prognosis in CN-AML patients. In addition, a large sample study by Papaemmanuil et al. (11) systematically perfected existing molecular classification system and especially pointed out that IDH2 (R172) but not IDH2 (R140) mutation was related to favorable prognosis in AML 7 The procedure of selecting studies was shown in Figure 1 . Firstly, 502 studies were retrieved from PubMed, Embase, Cochrane and Chinese databases (WanFang and CNKI), 197 of which were removed because of overlapping data sets. We screened the remaining 305 studies by browsing their titles and abstracts, excluded 225 studies for no association with our interest and chose 80 reports including articles and conference literatures for further evaluation. Of the 80 full-text studies, 47
were ruled out for the following reasons: 6 studies were only involved in pediatric leukemia; 3 reports were reviews; the data of 35 studies were incomplete or unavailable for analysis; the patient cohorts of 3 literatures overlapped with 3 other articles. The reviewers had perfect agreement in identifying the remaining 33 studies using the aforementioned eligibility criteria and all of identified manuscripts were with high quality (Table 1) .
Study characteristics
The characteristics of 33 studies were summarized in Table 1 (6, 10, 11, (16) (17) (18) (19) ,24-49): 13 studies from Europe and Australia, 10 from Asia, 8 from America and 2 collaborated studies from Asia, Africa and America as well as America, Japan and Germany, respectively, with a total sample size of 12747 cases. The frequency of IDH1 mutation was 2.02-9.30% in AML patients and 10.91-15.96 % in CN-AML patients, respectively, whereas the frequency of IDH2 mutation varied from 5.05% to 14.76% in AML subjects and from 5.85% to 19.27% in CN-AML cases, respectively. Fig. S1b, 1d ), respectively. Therefore, this study might be the source of significant heterogeneity, which needs further discussion.
As shown in Supplementary
These pooled HRs of OS and EFS suggested that when IDH1 and IDH2 mutation were analyzed together rather than separately, prognostic impact of these mutations were insignificant in AML or CN-AML patients. Interestingly, among IR-AML patients, the combined HRs of CIR was 1.44 (95% CI 1.18-1.76, p = 0.0003; heterogeneity: I 2 = 0.0%, p = 0.429) (Fig. 2d) .
Prognosis of AML patients with IDH1 mutation and SNP rs11554137
Due to prognostic ineffectiveness of IDH mutation, it was hypothesized that IDH1 and IDH2 Fig. S3 ). Since exclusion of any single study would not alter the aggregate result, subgroup analyses were also performed in Table 2 . Fig. S4a, 4b ).
In the aspect of treatment outcome of patients with mutant IDH2, the pooled RRs of CR rates were Fig. S5a, 5b) . Interestingly, the summary RRs of CR rates for the mutant IDH2 (R172) were 2.14 (95% CI 1.61-2.85, p = 0.0000; heterogeneity: I 2 = 16.4%, p = 0.302) ( Supplementary Fig. S5c ).
Sensitivity analyses
Research. In CN-AML patients with IDH mutations, sensitivity analysis revealed that the study by 
Subgroup analyses
With the advent of significant heterogeneity in OS for IDH and IDH2 (R140) mutations, we therefore performed subgroup analyses (Table 2) . Although the most important source of heterogeneity might be from different prognostic value of subtypes of IDH mutations, we did not performed related subgroup analyses for clear prognosis of each mutation has been shown above.
As shown in Table 2 , the original regions of samples, mutation direction methods, therapeutic schedules and data types had no effect on OS for mutant IDH and IDH2 (R140). However, in the aspect of mean/median age, younger people (mean/median age ≤ 50 years) with IDH mutations were with more consistency (HR: 0.91, 95% CI 0.80-1.02, heterogeneity: I 2 = 0.0%, p = 0.553) than other
Research. 
Publication bias
Egger's and Begg's tests were performed to evaluate publication bias and funnel plot symmetry was examined. No evident publication bias was observed based on the visual distribution of funnel plot ( Supplementary Fig. S6a , 6b, 6c) and p values in Egger's and Begg's tests (Supplementary Table   S2 ).
Comparing results from random effect model with those from fixed effect model
As shown in Supplementary Table S3, the analyses without heterogeneity (I 2 = 0.00%) had the same HRs or RRs and 95% CI in random effect model and fixed effect model. Additionally, HRs, RRs and 95% CI from the analyses with heterogeneity (I 2 > 0.00%) were slightly changed from random effect model to fixed effect model but it had no impact on prognostic analyses.
Discussion

Major findings
In this study, IDH mutations showed obviously different prognostic significance because of various subtypes. When IDH1 and IDH2 mutation were analyzed together rather than separately, there was no prognostic availability and great heterogeneity was observed in our analysis, both of which could be explained by the diverged impact of IDH1 and IDH2 mutations on survival. Our results have identified the prognostic value of each subtype of IDH mutations in AML patients, which might contribute to the application and therapeutic evaluation of target drugs in clinic.
Prognosis when combining with other mutations
As mentioned in Supplementary Table S1 , IDH mutations appear to be notably connected with (6, 18, 39) .
Comparison with other analyses
Our results were consistent with two other studies published previously: a meta-analysis (8) including 15 studies involved in IDH1 mutation in AML and another one (9) covering 13 studies associated with IDH1 and IDH2 mutation in non-promyelocytic AML. Both found that IDH1 mutation was correlated with poor prognosis whereas opposite prognosis was observed in IDH2 mutation. Our meta-analysis contained 33 publications and included 12747 cases in total, a larger scale study that could significantly increase the statistical power and accurately assess the prognostic impact of IDH mutations on AML patients. Another significant feature of our research is that the populations included were broadly from Europe, Asia, Australia and America. Hence, our meta-analysis promised an extensive utilization of IDH mutations in the prognosis of AML patients.
More importantly, we investigated more endpoints of survival and treatment outcome. IDH mutations had no impact on OS and EFS if integrated as a single factor. For mutant IDH1, we not only performed analyses about OS and EFS in AML and CN-AML cases, but also found that IDH1 SNP rs11554137 was correlated with poor prognosis for AML patients, a finding previously not reported in the two meta-analyses. We also noted that mutant IDH1 was more unfavorable for OS in CN-AML cases, which was not shown in the two previous analyses. We found that IDH2 mutation was not only associated with prolonged OS but more linked to favorable prognosis among IR-AML patients, which was also not shown in the two previous articles. We found that mutant IDH2 (R140) but not IDH2 (R172) was correlated with longer OS in subgroup analyses, a novel finding as well. The diamond represents the pooled HRs and 95% CI. The p value less than 0.05 was considered statistically significant. 
